183 related articles for article (PubMed ID: 37282505)
1. Edoxaban Versus Low-Molecular-Weight Heparin in Hospitalized COVID-19 Patients With Atrial Fibrillation.
Olivera P; Velásquez-Escandón C; Campoy D; Flores K; Canals T; Johansson E; Herranz MJ; Martínez L; Cerezo-Manchado JJ; Salinas R
Clin Appl Thromb Hemost; 2023; 29():10760296231180865. PubMed ID: 37282505
[TBL] [Abstract][Full Text] [Related]
2. Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG - RAPID Trial): A structured summary of a study protocol for a randomised controlled trial.
Sholzberg M; Tang GH; Negri E; Rahhal H; Kreuziger LB; Pompilio CE; James P; Fralick M; AlHamzah M; Alomran F; Tseng E; Lim G; Lillicrap D; Carrier M; Áinle FN; Beckett A; da Costa BR; Thorpe K; Middeldorp S; Lee A; Cushman M; Jüni P
Trials; 2021 Mar; 22(1):202. PubMed ID: 33691765
[TBL] [Abstract][Full Text] [Related]
3. Impact of atrial fibrillation and anticoagulation on the risk of death, thromboembolic disease and bleeding in patients with COVID-19: the ACO-VID Registry.
Cerezo Manchado JJ; Iturbe Hernández T; Martínez Pacheco MDC; Gil Ortega I; Campoy D; Canals Pernas T; Martínez Serra L; Flores Aparco KJ; Velásquez Escandón CA; Martínez Francés A; Olivera P
Curr Med Res Opin; 2023 Jun; 39(6):811-817. PubMed ID: 37189306
[TBL] [Abstract][Full Text] [Related]
4. Relation of Stroke and Bleeding Risk Profiles to Efficacy and Safety of Edoxaban for Cardioversion of Atrial Fibrillation (from the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation [ENSURE-AF] Study).
Lip GYH; Merino JL; Dan GA; Themistoclakis S; Ellenbogen KA; De Caterina R; Goudev A; Jin J; Melino M; Winters SM; Goette A
Am J Cardiol; 2018 Jan; 121(2):193-198. PubMed ID: 29169605
[TBL] [Abstract][Full Text] [Related]
5. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY
J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744
[TBL] [Abstract][Full Text] [Related]
6. Predictors of warfarin use in atrial fibrillation patients in the inpatient setting.
Agarwal S; Bennett D; Smith DJ
Am J Cardiovasc Drugs; 2010; 10(1):37-48. PubMed ID: 20104933
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe).
De Caterina R; Kelly P; Monteiro P; Deharo JC; de Asmundis C; López-de-Sá E; Weiss TW; Waltenberger J; Steffel J; de Groot JR; Levy P; Bakhai A; Zierhut W; Laeis P; Kerschnitzki M; Reimitz PE; Kirchhof P;
BMC Cardiovasc Disord; 2019 Jul; 19(1):165. PubMed ID: 31299906
[TBL] [Abstract][Full Text] [Related]
8. Pharmacotherapy of atrial fibrillation in COVID-19 patients.
Tomaszuk-Kazberuk A; Koziński M; Domienik-Karłowicz J; Jaguszewski M; Darocha S; Wybraniec M; Dobrowolski P; Kupczyńska K; Michalski B; Wańha W; Kapłon-Cieślicka A
Cardiol J; 2021; 28(5):758-766. PubMed ID: 34382204
[TBL] [Abstract][Full Text] [Related]
9. Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation.
Fox KAA; Lucas JE; Pieper KS; Bassand JP; Camm AJ; Fitzmaurice DA; Goldhaber SZ; Goto S; Haas S; Hacke W; Kayani G; Oto A; Mantovani LG; Misselwitz F; Piccini JP; Turpie AGG; Verheugt FWA; Kakkar AK;
BMJ Open; 2017 Dec; 7(12):e017157. PubMed ID: 29273652
[TBL] [Abstract][Full Text] [Related]
10. Immediate post-procedure bridging with unfractioned heparin versus low molecular weight heparin in patients undergoing radiofrequency ablation for atrial fibrillation with an interrupted oral anticoagulation strategy.
Loughlin G; Romaniega TD; Garcia-Fernandez J; Calvo D; Salgado R; Alonso A; Li X; Arenal A; González-Torrecilla E; Atienza F; Fernández-Avilés F
J Interv Card Electrophysiol; 2016 Mar; 45(2):149-58. PubMed ID: 26739484
[TBL] [Abstract][Full Text] [Related]
11. Predictive Factors and Clinical Events Associated with Edoxaban Interruption and Heparin Bridging Strategy: EMIT-AF/VTE.
Santamaria A; Chen C; Colonna P; von Heymann C; Saxena M; Vanassche T; Jin J; Unverdorben M
Clin Appl Thromb Hemost; 2023; 29():10760296231200223. PubMed ID: 37697813
[TBL] [Abstract][Full Text] [Related]
12. Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATE-AF study.
Hohnloser SH; Camm J; Cappato R; Diener HC; Heidbuchel H; Lanz HJ; Mont L; Morillo CA; Smolnik R; Yin OQP; Kautzner J
Clin Cardiol; 2018 Apr; 41(4):440-449. PubMed ID: 29663464
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of bleeding secondary to anticoagulation and mortality in patients with atrial fibrillation admitted with SARS-CoV-2 infection.
Rubini-Costa R; Bermúdez-Jiménez F; Rivera-López R; Sola-García E; Nagib-Raya H; Moreno-Escobar E; López-Zúñiga MÁ; Briones-Través A; Sanz-Herrera F; Sequí-Sabater JM; Romero-Cabrera JL; Maíllo-Seco J; Fernández-Vázquez F; Rivadeneira-Ruiz M; López-Valero L; Gómez-Navarro C; Aparicio-Gómez JA; López MÁ; Tercedor L; Molina-Jiménez M; Macías-Ruiz R; Jiménez-Jáimez J
Med Clin (Barc); 2022 Jun; 158(12):569-575. PubMed ID: 34364707
[TBL] [Abstract][Full Text] [Related]
14. Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis.
Caldeira D; Rodrigues FB; Barra M; Santos AT; de Abreu D; Gonçalves N; Pinto FJ; Ferreira JJ; Costa J
Heart; 2015 Aug; 101(15):1204-11. PubMed ID: 26037103
[TBL] [Abstract][Full Text] [Related]
15. Low-molecular-weight heparin use in coronavirus disease 2019 is associated with curtailed viral persistence: a retrospective multicentre observational study.
Pereyra D; Heber S; Schrottmaier WC; Santol J; Pirabe A; Schmuckenschlager A; Kammerer K; Ammon D; Sorz T; Fritsch F; Hayden H; Pawelka E; Krüger P; Rumpf B; Traugott MT; Glaser P; Firbas C; Schörgenhofer C; Seitz T; Karolyi M; Pabinger I; Brostjan C; Starlinger P; Weiss G; Bellmann-Weiler R; Salzer HJF; Jilma B; Zoufaly A; Assinger A
Cardiovasc Res; 2021 Dec; 117(14):2807-2820. PubMed ID: 34609480
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF).
Rohla M; Weiss TW; Pecen L; Patti G; Siller-Matula JM; Schnabel RB; Schilling R; Kotecha D; Lucerna M; Huber K; De Caterina R; Kirchhof P
BMJ Open; 2019 Mar; 9(3):e022478. PubMed ID: 30928922
[TBL] [Abstract][Full Text] [Related]
17. Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis.
Sterne JA; Bodalia PN; Bryden PA; Davies PA; López-López JA; Okoli GN; Thom HH; Caldwell DM; Dias S; Eaton D; Higgins JP; Hollingworth W; Salisbury C; Savović J; Sofat R; Stephens-Boal A; Welton NJ; Hingorani AD
Health Technol Assess; 2017 Mar; 21(9):1-386. PubMed ID: 28279251
[TBL] [Abstract][Full Text] [Related]
18. Impact of New Onset Atrial Fibrillation in Hospitalized Patients with COVID-19. Results of the "ACO-VID" Registry.
Cerezo Manchado JJ; Iturbe Hernández T; Martínez Pacheco MDC; Gil Ortega I; Campoy D; Canals Pernas T; Martinez Serra L; Flores Aparco KJ; Velasquez Escandon CA; García de Guadiana-Romualdo L; Martinez Frances A; Olivera P
Clin Appl Thromb Hemost; 2023; 29():10760296231208440. PubMed ID: 37899606
[TBL] [Abstract][Full Text] [Related]
19. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
Míka P; Behounek J; Skoták M; Nevsímal L
Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
[TBL] [Abstract][Full Text] [Related]
20. Edoxaban for stroke prevention in atrial fibrillation and age-adjusted predictors of clinical outcomes in routine clinical care.
Kirchhof P; Pecen L; Bakhai A; de Asmundis C; de Groot JR; Deharo JC; Kelly P; Levy P; Lopez-de-Sa E; Monteiro P; Steffel J; Waltenberger J; Weiss TW; Laeis P; Manu MC; Souza J; De Caterina R
Eur Heart J Cardiovasc Pharmacother; 2022 Dec; 9(1):47-57. PubMed ID: 35881467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
